These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. Meyer S; Leusen JH; Boross P MAbs; 2014; 6(5):1133-44. PubMed ID: 25517299 [TBL] [Abstract][Full Text] [Related]
3. The role of complement in mAb-based therapies of cancer. Taylor RP; Lindorfer MA Methods; 2014 Jan; 65(1):18-27. PubMed ID: 23886909 [TBL] [Abstract][Full Text] [Related]
4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ MAbs; 2015; 7(3):494-504. PubMed ID: 25933349 [TBL] [Abstract][Full Text] [Related]
5. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy. Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412 [TBL] [Abstract][Full Text] [Related]
7. Complement as a Biological Tool to Control Tumor Growth. Macor P; Capolla S; Tedesco F Front Immunol; 2018; 9():2203. PubMed ID: 30319647 [TBL] [Abstract][Full Text] [Related]
8. Complement in antibody-based tumor therapy. Derer S; Beurskens FJ; Rosner T; Peipp M; Valerius T Crit Rev Immunol; 2014; 34(3):199-214. PubMed ID: 24941073 [TBL] [Abstract][Full Text] [Related]
9. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Masui H; Moroyama T; Mendelsohn J Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906 [TBL] [Abstract][Full Text] [Related]
11. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181 [TBL] [Abstract][Full Text] [Related]
13. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079 [TBL] [Abstract][Full Text] [Related]
14. New perspectives on complement mediated immunotherapy. Stasiłojć G; Österborg A; Blom AM; Okrój M Cancer Treat Rev; 2016 Apr; 45():68-75. PubMed ID: 26994325 [TBL] [Abstract][Full Text] [Related]
16. Complement and cellular cytotoxicity in antibody therapy of cancer. Wang SY; Weiner G Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Taylor RP; Lindorfer MA Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480 [TBL] [Abstract][Full Text] [Related]
18. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221 [TBL] [Abstract][Full Text] [Related]